Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients

This is Phase 2, open-label, multicentre, non-randomised study evaluating participants with newly diagnosed MM eligible for high-dose therapy. The goal of the study is to determine if consolidation with T-cell redirectors - Talquetamab and Teclistamab in sequence will improve the response depth: increase MRD negative CR rate.

NCT Number	NCT06505369
Lead Sponsor	North Estonia Medical Centre Collaborators: Janssen Pharmaceutica
Conditions	Multiple Myeloma
Enrollment	50 participants
Start Date	2024-06-19
Primary Completion	2026-11 (estimated)
Study Completion	2028-10 (estimated)
Updated on ClinicalTrials.gov	2024-07-17